Obesity is a huge problem, not only for personal health, but also for social health. This is because it is considered to be the cause of many secondary diseases, including cardiovascular disease and diabetes. DJE expert Sebastian Hofbeck, analyst for the pharmaceutical sector, explains the phenomenon surrounding weight loss injections. According to the WHO, around 650 million people currently suffer from obesity - and this figure could rise to around one billion people by 2030. Obesity would thus reach epidemic proportions.
Two companies are therefore very popular with their recently developed weight loss products: the Danish pharmaceutical company Novo Nordisk has become the largest European company, Eli Lilly the largest US pharmaceutical company.
The weight loss injections are a rather fortuitous result of diabetes research, but are effective in combating obesity: both the feeling of hunger and gastric emptying are reduced by the active ingredient, a GLP-1 agonist. It also stimulates the pancreas to produce more insulin. GLP stands for "glucagon-like peptide" and mimics the effect of the body's own hormones.
According to current studies by the two pharmaceutical giants, the injections could also have a significant effect in cardiovascular diseases, such as heart attacks, strokes or heart failure, chronic kidney failure or sleep apnoea.
The size of the potential market for GLP-1 syringes, the challenges that exist and whether the competition could still come into play are the topics of the interview that DJE expert Sebastian Hofbeck, analyst for the pharmaceutical sector, gave to ARD for "Update Wirtschaft".
The interview with Sebastian Hofbeck in "Update Wirtschaft" from 05.08.2024 on ARD can be seen here from <u>minute 09:30</u>
NOTE: This is a marketing advertisement. Please read the prospectus of the fund in question and the KIID before making a final investment decision. This also contains detailed information on opportunities and risks. These documents are available free of charge in German at www.dje.de under the fund in question. A summary of investor rights is available free of charge in German in electronic form on the website at www.dje.de/zusammenfassung-der-anlegerrechte free of charge. All information published here is for your information only, is subject to change at any time and does not constitute investment advice or any other recommendation.